UGT1A3 and neoplasm: Our previous results demonstrated that UGT1A3 was highly expressed in LUAD and associated with poor prognosis, inhibiting UGT1A3 showed significant anti-cancer effects by enhancing the activity of anti-tumor drugs (Wang et al., 2019).